| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenues | 10,882 | 10,052 | ||
| Provision (benefit) for credit losses | -931 | 761 | ||
| Loss on impairment of intangibles assets | 209 | 0 | ||
| Loss on disposal of inventory | 314 | - | ||
| Interest expense | 1,179 | 1,155 | ||
| Pharmaceutical manufacturing, research and development expense | 147 | 645 | ||
| Change in fair value of acquisition-related contingent consideration | 0 | 0 | ||
| Depreciation and amortization expense | 2 | 19 | ||
| General and administrative expense | 3,286 | 2,843 | ||
| Income from operations | 6,676 | 4,629 | ||
| Unrealized net gains on warrants | 2,640 | 347 | ||
| Net gain on exercise and cancellation of warrants | 0 | 0 | ||
| Loss on sale of assets | 0 | 0 | ||
| Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax | 1,601 | - | ||
| Net loss on marketable investments | -246 | 37 | ||
| Realized gain on early payment of finance receivable | 0 | 0 | ||
| Gain (loss) on revaluation of finance receivables | 0 | 0 | ||
| Realized and unrealized foreign currency transaction gains (losses) | 25 | -451 | ||
| Income before income tax expense | 10,696 | 4,562 | ||
| Income tax expense | 1,916 | 1,026 | ||
| Net income | 8,780 | 3,536 | ||
| Basic (in dollars per share) | 0.72 | 0.29 | ||
| Basic (in shares) | 12,117,000 | 12,208,000 | ||
| Diluted (in dollars per share) | 0.72 | 0.29 | ||
| Diluted (in shares) | 12,117,000 | 12,208,000 | ||
SWK Holdings Corp (SWKHL)
SWK Holdings Corp (SWKHL)